Clinical trial of chlorozotocin, DTIC, and dactinomycin in metastatic malignant melanoma.
Thirty evaluable patients with metastatic malignant melanoma were treated with a combination of chlorozotocin, DTIC, and dactinomycin. One complete and four partial responses were achieved, for an overall response rate of 17%. Cumulative myelotoxicity was noted, as well as universal gastrointestinal intolerance. One patient developed probable drug-related nephrotoxicity. A survival advantage was noted for responding patients. We conclude that the addition of chlorozotocin did not improve response rate or response duration and that further trials with this drug combination cannot be recommended.
D000293:Adolescent; D000328:Adult; D001853:Bone Marrow / Q000187:drug effects; D002986:Clinical Trials as Topic; D003606:Dacarbazine / Q000008:administration & dosage* / Q000009:adverse effects; D003609:Dactinomycin / Q000008:administration & dosage* / Q000009:adverse effects; D004064:Digestive System / Q000187:drug effects; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007668:Kidney / Q000187:drug effects; D008297:Male; D008545:Melanoma / Q000188:drug therapy*; D008875:Middle Aged; D009362:Neoplasm Metastasis; D013311:Streptozocin / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*
D003609:Dactinomycin; C007028:chlorozotocin; D013311:Streptozocin; D003606:Dacarbazine